Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.57 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | TYMS | P04818 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL10985661 | 0.98 | FABP6 (0.96) | FABP6MEN1KMT2AMAPTATM | |
| Bromide SCHEMBL23295657 | 0.98 | FABP6 (0.96) | FABP6MEN1KMT2AMAPTATM | |
| SCHEMBL14247949 | 0.84 | FABP6 (0.72) | FABP6MEN1KMT2AMAPTATM | |
| SCHEMBL5680925 | 0.84 | FABP6 (0.72) | FABP6MEN1KMT2AMAPTATM | |
| SCHEMBL8239403 | 0.84 | FABP6 (0.72) | FABP6MEN1KMT2AMAPTATM | |
| SCHEMBL5924162 | 0.84 | FABP6 (0.72) | FABP6MEN1KMT2AMAPTATM | |
| SCHEMBL27661513 | 0.83 | FABP6 (0.70) | FABP6MEN1KMT2AMAPTATM | |
| SCHEMBL27681183 | 0.83 | FABP6 (0.70) | FABP6MEN1KMT2AMAPTATM | |
| SCHEMBL11367412 | 0.83 | FABP6 (0.70) | FABP6MEN1KMT2AMAPTATM | |
| SCHEMBL11367405 | 0.83 | FABP6 (0.70) | FABP6MEN1KMT2AMAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110136982-B | Composite fabric electrode for flexible supercapacitor and preparation and application thereof | 东华大学 | 2021-03-19 | — | — | CN | claimed |
| CN-110136982-A | A kind of flexible super capacitor compound fabric electrode and its preparation and application | 东华大学 | 2019-08-16 | — | — | CN | claimed |
| US-10292390-B2 | Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-05-21 | — | — | US | claimed |
| EP-2742029-B1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| WO-2016154110-A1 | COMPANION DIAGNOSTIC FOR P97 INHIBITOR THERAPY AND METHODS OF USE THEREOF | CLEAVE BIOSCIENCES, INC. (US) | 2016-09-29 | — | — | WO | claimed |
| CN-104768946-A | Fused pyrimidines as inhibitors of the p97 complex | CLEAVE BIOSCIENCES INC | 2015-07-08 | — | — | CN | claimed |
| EP-2875018-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2015-05-27 | — | — | EP | claimed |
| US-8912202-B2 | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists | MERCK PATENT GMBH (DE) | 2014-12-16 | — | — | US | claimed |
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| EP-2742029-A1 | N-(BENZIMIMDAZOL-2-YL)-CYCLOPROPANE CARBOXAMIDES AS LYSOPHOSPHATIDIC ACID ANTAGONISTS | Merck Patent GmbH (DE) | 2014-06-18 | — | — | EP | claimed |
| US-20120156589-A1 | ELECTRODE CATALYST FOR FUEL CELL, MANUFACTURING METHOD THEREOF, AND FUEL CELL USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-06-21 | — | — | US | claimed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-6846525-B2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 2005-01-25 | — | — | US | claimed |
| US-20040202825-A1 | RECORDING SHEETS CONTAINING PURINE, PYRIMIDINE, BENZIMIDAZOLE, IMIDAZOLIDINE, URAZOLE, PYRAZOLE, TRIAZOLE, BENZOTRIAZOLE, TETRAZOLE, AND PYRAZINE COMPOUNDS | XEROX CORPORATION | 2004-10-14 | — | — | US | claimed |
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228378-A1 | N-(Benzimimdazol-2-yl)-Cyclopropane Carboxamides as Lysophosphatidic Acid Antagonists | LPAR5, LPAR2, LPAR1 | FABP6 1397/4885MEN1 2688/4885KMT2A 1545/4885 |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | FABP6 952/4885MEN1 2080/4885KMT2A 1047/4885 |
| US-10292390-B2 | Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives | FLNB, BRI3BP, CCNI | FABP6 2758/4885MEN1 3710/4885KMT2A 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.